OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in cellular and infection microbiology
2019;9 422.

Synergetic Effects of Combined Treatment of Colistin With Meropenem or Amikacin on Carbapenem-Resistant .

Lan Yu, Jisheng Zhang, Yanjun Fu, Yongxin Zhao, Yong Wang, Jing Zhao, Yuhang Guo, Chunjiang Li, Xiaoli Zhang
Author Information
  1. Lan Yu: Department of Microbiology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
  2. Jisheng Zhang: Department of Microbiology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
  3. Yanjun Fu: Department of Microbiology, The First Affiliated Hospital of Jiamusi University, Jiamusi, China.
  4. Yongxin Zhao: Department of Microbiology, The First Affiliated Hospital of Jiamusi University, Jiamusi, China.
  5. Yong Wang: Department of Microbiology, The First Affiliated Hospital of Jiamusi University, Jiamusi, China.
  6. Jing Zhao: Department of Scientific Research Section, Jiamusi University School of Clinical Medicine, Jiamusi, China.
  7. Yuhang Guo: Department of Microbiology, The First Affiliated Hospital of Jiamusi University, Jiamusi, China.
  8. Chunjiang Li: Department of Pathogenic Biology, Jiamusi University School of Basic Medicine, Jiamusi, China.
  9. Xiaoli Zhang: Department of Microbiology, Yongchuan Hospital of Chongqing Medical University, Chongqing, China.
PMID: 31921701 DOI: 10.3389/fcimb.2019.00422

Abstract

The purpose of this study was to investigate the synergistic and bactericidal effects of combinations of colistin with meropenem or amikacin and provide laboratory data needed for development of therapeutic strategies for the treatment of carbapenem-resistant (CRKP) infection. We found that minimum inhibitory concentration (MIC) of colistin, meropenem and amikacin were 2~32, 4~256, and 1~16384 μg/ml, respectively. The minimum bactericidal concentration of the antibiotics was either 1× or 2×MIC. Treatments of 6 CRKP isolates at 1 μg/ml colistin completely killed 2 of them and suppressed 4 others growth. 4 CRKP isolates at 16 μg/ml meropenem or amikacin completely killed and suppressed 2 others growth. 2 CRKP isolates showed synergic effects in all colistin combination and 3 CRKP isolates showed synergic effects in part of colistin combination. Our data suggest that colistin in combination with either meropenem or amikacin could be a valid therapeutic option against colistin-resistant CRKP isolates. Moreover, the combination of colistin-amikacin is less expensive to treat CRKP infections in Eastern Heilongjiang Province.

Keywords

bactericidal effect carbapenem-resistant Klebsiella pneumoniae colistin combination therapy synergistic effect

References

  1. Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1739-1748 [PMID: 28470337]
  2. Diagn Microbiol Infect Dis. 2018 Nov;92(3):262-266 [PMID: 30098852]
  3. Front Microbiol. 2017 Mar 16;8:422 [PMID: 28360902]
  4. BMC Infect Dis. 2018 Aug 22;18(1):417 [PMID: 30134844]
  5. J Antimicrob Chemother. 2011 Apr;66(4):946-7 [PMID: 21393203]
  6. Infect Control Hosp Epidemiol. 2008 Dec;29(12):1099-106 [PMID: 18973455]
  7. Antimicrob Agents Chemother. 2015 May;59(5):2909-13 [PMID: 25691646]
  8. Clin Infect Dis. 2018 Nov 13;67(suppl_2):S225-S230 [PMID: 30423052]
  9. AIMS Microbiol. 2018 Jun 26;4(3):482-501 [PMID: 31294229]
  10. Lancet Infect Dis. 2017 Mar;17(3):256-257 [PMID: 28244381]
  11. Biomed Res Int. 2015;2015:679109 [PMID: 25664322]
  12. Lancet. 1997 Feb 8;349(9049):418-22 [PMID: 9033483]
  13. Lancet Infect Dis. 2016 Feb;16(2):161-8 [PMID: 26603172]
  14. Antimicrob Agents Chemother. 2015 Nov 02;60(1):431-6 [PMID: 26525802]
  15. Microb Drug Resist. 2019 Mar;25(2):152-156 [PMID: 30109975]
  16. Antimicrob Agents Chemother. 2014;58(1):212-20 [PMID: 24145532]
  17. Antimicrob Agents Chemother. 2014 Oct;58(10):5696-703 [PMID: 25022583]
  18. Nat Microbiol. 2019 Oct;4(10):1627-1635 [PMID: 31209306]
  19. J Antibiot (Tokyo). 2015 Jun;68(6):395-8 [PMID: 25586022]
  20. Infect Immun. 2000 Nov;68(11):6139-46 [PMID: 11035717]
  21. Int J Antimicrob Agents. 2014 Dec;44(6):500-7 [PMID: 25264127]
  22. J Biol Chem. 2007 Dec 7;282(49):36077-89 [PMID: 17928292]
  23. Antimicrob Agents Chemother. 2015 Mar;59(3):1466-71 [PMID: 25534730]
  24. mBio. 2018 Mar 6;9(2): [PMID: 29511071]
  25. Expert Rev Anti Infect Ther. 2007 Oct;5(5):811-21 [PMID: 17914915]
  26. J Bacteriol. 2006 Jun;188(11):3995-4006 [PMID: 16707691]
  27. J Antimicrob Chemother. 2006 Mar;57(3):573-6 [PMID: 16431863]
  28. J Clin Microbiol. 2014 Dec;52(12):4124-8 [PMID: 24920779]
  29. Antimicrob Agents Chemother. 2014;58(3):1757-62 [PMID: 24395223]
  30. Einstein (Sao Paulo). 2019 May 16;17(4):eGS4444 [PMID: 31116310]
  31. J Anaesthesiol Clin Pharmacol. 2017 Jul-Sep;33(3):300-305 [PMID: 29109626]
  32. Front Microbiol. 2017 Jan 23;8:51 [PMID: 28167938]
  33. Lancet Infect Dis. 2017 Feb;17(2):153-163 [PMID: 27866944]

MeSH Term

Amikacin
Anti-Bacterial Agents
Carbapenem-Resistant Enterobacteriaceae
Colistin
Drug Resistance, Multiple, Bacterial
Drug Synergism
Drug Therapy, Combination
Enterobacteriaceae Infections
Humans
Meropenem
Microbial Sensitivity Tests
Multilocus Sequence Typing

Chemicals

Anti-Bacterial Agents
Amikacin
Meropenem
Colistin
Journal Article Research Support, Non-U.S. Gov't
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0colistinCRKPisolatescombinationmeropenemamikacinbactericidaleffectsμg/ml2synergisticdatatherapeuticcarbapenem-resistantminimumconcentrationeithercompletelykilledsuppressed4othersgrowthshowedsynergiceffectpurposestudyinvestigatecombinationsprovidelaboratoryneededdevelopmentstrategiestreatmentinfectionfoundinhibitoryMIC2~324~2561~16384respectivelyantibiotics1×2×MICTreatments61163partsuggestvalidoptioncolistin-resistantMoreovercolistin-amikacinlessexpensivetreatinfectionsEasternHeilongjiangProvinceSynergeticEffectsCombinedTreatmentColistinMeropenemAmikacinCarbapenem-ResistantKlebsiellapneumoniaetherapy

Similar Articles

Cited By